TRANSCENTA-B (06628) Receives First Installment Payment for Sale of CDMO Assets
Transcenta Holding (06628) announced that, among other things, it has sold CDMO assets to the buyer (a wholly-owned subsidiary of WuXi Biologics) for a total consideration of RMB190 million. As of the date of this announcement, the Group has received from the buyer the first installment payment of the consideration on a net-of-tax basis, amounting to RMB95 million, in accordance with the terms of the asset purchase agreement. The proceeds received will be used to supplement the Group's general working capital and to develop the Group's product pipeline.
TRANSCENTA-B (06628) Announces First Installment Payment Received for Sale of CDMO Assets
TRANSCENTA-B (06628) issued an announcement regarding, among other things, the sale of CDMO assets to the buyer (a wholly-owned subsidiary of WuXi Biologics) for a total consideration of RMB 190 million. As of the date of this announcement, the Group has received from the buyer the first installment payment of the consideration on a net-of-tax basis, amounting to RMB 95 million, in accordance with the terms of the asset purchase agreement. The proceeds received will be used to supplement the Group's general working capital and to develop the Group's product pipeline.
As a result of the sale of CDMO assets, the Group's labor costs and operating expenses are expected to decrease in 2027 compared to 2026. The handover of the CDMO assets is in progress, and the Company expects to receive additional proceeds before the end of 2026, subject to the relevant terms and conditions of the asset purchase agreement.
Related Articles
HK Stock Market Move | Chinese brokerage stocks extend afternoon losses as brokerages approach Q3 earnings disclosure period; institutions say quarterly profit affected by direct investment and co-investment disruptions.
China Great Wall: Initiates "Buy" rating on CHINAHONGQIAO (01378); electrolytic aluminum profitability stands out, high dividend payout highlights investment value.
HK Stock Market Move | KEYMED BIO-B (02162) rose more than 6% in the afternoon; Kangyueda's indication for adolescent atopic dermatitis approved for marketing
HK Stock Market Move | Chinese brokerage stocks extend afternoon losses as brokerages approach Q3 earnings disclosure period; institutions say quarterly profit affected by direct investment and co-investment disruptions.
China Great Wall: Initiates "Buy" rating on CHINAHONGQIAO (01378); electrolytic aluminum profitability stands out, high dividend payout highlights investment value.
HK Stock Market Move | KEYMED BIO-B (02162) rose more than 6% in the afternoon; Kangyueda's indication for adolescent atopic dermatitis approved for marketing
